Margaret G. McGlynn is President and CEO of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. She joined the organization in July 2011, and had been a member of its Board of Directors since July 2010.
Margaret is an experienced biopharmaceutical executive with significant expertise in the vaccine and antiretroviral markets. She retired from Merck in 2009 after 26 years with the company. Her most recent role was President, Global Vaccines and Anti-Infectives, where she was responsible for a US$7 billion portfolio of products. In addition, she was very involved in global health, and she launched several initiatives to provide access for Merck vaccines and HIV therapies in the developing world. She also served on the board and executive committee of The GAVI Alliance, a public-private partnership to bring life-saving vaccines against common infectious diseases to people across the developing world, and she played a major role in the formation of the Hilleman Center, a research center focused on developing new vaccines for the developing world, via a partnership between Merck and the Wellcome Trust.
